2 results
Approved WMORecruiting
To assess the feasibility and efficacy of 90Y-ibritumomab tiuxetan consolidation treatment after R-PECC chemotherapy as second or third line treatment in patients with refractory or relapsed aggressive B-cell NHL, after or not eligible for…
Approved WMOCompleted
Primary objectives:# To evaluate the safety of the combination of JNJ-63723283 with apalutamide.# To define a population of subjects with metastatic CRPC who respond to treatment with the combination of JNJ-63723283 and apalutamide.Secondary…